Cepheid Receives Health Canada License for Xpert(R) HemosIL(R) FII & FV Test



    On-Demand Test for Genetic Risk of Thrombosis Improves Time-to-Result
over Current Molecular Tests

    SUNNYVALE, Calif. and BEDFORD, Mass., June 3 /PRNewswire-FirstCall/ --
Cepheid (Nasdaq:   CPHD) and Instrumentation Laboratory today announced that
Health Canada has issued Cepheid a medical device license for its Xpert
HemosIL FII & FV test. The test detects Factor II (FII) and Factor V Leiden
(FV) genetic variations associated with thrombophilia, an increased risk of
blood clots (thrombosis). Xpert HemosIL FII & FV delivers results in just over
thirty minutes using a single GeneXpert(R) cartridge. Developed and
manufactured by Cepheid, the test will be available in Canada through a
partnership with Instrumentation Laboratory (IL), the exclusive worldwide
distributor for the Xpert HemosIL FII & FV test.

    "Given the complexity of traditional molecular diagnostics, clinical
laboratories currently may wait up to a week for FII and FV genotyping," said
John Bishop, Chief Executive Officer at Cepheid. "The Xpert HemosIL FII & FV
test will allow Canadian laboratories to perform the test on-demand -- and
integrate the results with other tests -- providing physicians a more
comprehensive thrombophilia profile of their patients."

    FII and FV are the most common hereditary risk factors for venous
thrombosis and key in the determination of genetic predisposition to the
condition and the need for prophylactic treatment in high-risk patients.
Testing for genetic and acquired defects, which may lead to thrombosis, is
performed with the aid of both classic coagulation assays and molecular tests.
In the past, many of these molecular tests could not be performed in a
traditional hospital laboratory. Now, Cepheid's GeneXpert System enables
on-demand FII and FV molecular tests to be easily performed in the hospital or
independent clinical laboratory.

    "This license for Xpert HemosIL FII & FV allows us to begin coordinating
the commercialization of the product in Canada, with our partner, Beckman
Coulter, Inc.  This unique test will be a valuable addition to our robust
HemosIL product line of fully automated assays in Canadian hemostasis
laboratories," said Josep Manent, Chief Executive Officer of IL.  "In
combination with our ACL TOP(R) Family of Testing Systems, the Xpert HemosIL
test on the GeneXpert System will enable our Canadian customers to perform a
complete thrombophilia work-up, rapidly, efficiently and accurately."

    Xpert HemosIL FII & FV is the sixth GeneXpert-based test to receive a
Health Canada Medical Device License.
    

    About Instrumentation Laboratory
    
    Instrumentation Laboratory (www.ilus.com), founded in 1959, is a
worldwide developer, manufacturer and distributor of in vitro diagnostic
instruments, related reagents and controls for use primarily in hospitals and
independent clinical laboratories.  The company's product lines include
critical care systems, hemostasis systems and information management systems. 
IL's hemostasis portfolio includes the ACL TOP(R) Family of Hemostasis Testing
Systems, fully automated, high-productivity analyzers, including the ACL TOP
and the new ACL TOP 500 CTS.  IL also offers the new ACL AcuStar Hemostasis
Testing System, the ACL ELITE(R) and ELITE PRO, other hemostasis analyzers and
the HemosIL(R) line of reagents. IL's GEM(R) product offerings, part of the
critical care line, include the GEM Premier(TM) 4000 analyzer with Intelligent
Quality Management (iQM(R)), the new GEM Premier 3500 analyzer with iQM and
the GEM PCL Plus, a portable coagulation analyzer.   IL is based in Bedford,
Massachusetts.
    

    About Cepheid
    
    Based in Sunnyvale, Calif., Cepheid (Nasdaq:   CPHD) is an on-demand
molecular diagnostics company that develops, manufactures, and markets
fully-integrated systems and tests for genetic analysis in the clinical,
industrial and biothreat markets. The company's systems enable rapid,
sophisticated genetic testing for organisms and genetic-based diseases by
automating otherwise complex manual laboratory procedures. The company's
easy-to-use systems integrate a number of complicated and time-intensive
steps, including sample preparation, DNA amplification and detection, which
enable the analysis of complex biological samples in its proprietary test
cartridges. Through its strong molecular biology capabilities, the company is
focusing on those applications where rapid molecular testing is particularly
important, such as identifying infectious disease and cancer in the clinical
market; food, agricultural, and environmental testing in the industrial
market; and identifying bio-terrorism agents in the biothreat market. See
http://www.cepheid.com for more information.

    This press release contains forward-looking statements that are not
purely historical regarding Cepheid's or its management's intentions, beliefs,
expectations and strategies for the future, including those relating to
product performance. Because such statements deal with future events, they are
subject to various risks and uncertainties, and actual results could differ
materially from the company's current expectations. Factors that could cause
actual results to differ materially include risks and uncertainties such as
those relating to: unforeseen manufacturing problems; regulatory developments
and practices regarding testing; the failure of products to perform as
expected, whether due to manufacturing errors, defects or otherwise; the
impact of competitive products. Readers should also refer to the section
entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2008 and
in its most recent quarterly report on Form 10-Q, each filed with the
Securities and Exchange Commission.

    All forward-looking statements and reasons why results might differ
included in this release are made as of the date of this press release, based
on information currently available to Cepheid, and Cepheid assumes no
obligation to update any such forward-looking statement or reasons why results
might differ.

    The Instrumentation Laboratory logo, HemosIL, ACL, ACL TOP, ACL ELITE,
ACL AcuStar, iQM GEM, Premier and GEM OPL are trademarks of Instrumentation
Laboratory Company and/or one of its subsidiaries or parent companies, and may
be registered in the United States Patent and Trademark Office and in other
jurisdictions.


    
     Media Inquiries at Cepheid:
     ---------------------------
     Jared Tipton
     Cepheid Corporate Communications
     408-400-8377
     jared.tipton@cepheid.com
    

    
     Investor Inquiries at Cepheid:
     ------------------------------
     Jacquie Ross
     Cepheid Investor Relations
     408-400-8329
     investor.relations@cepheid.com
    

    
     At Instrumentation Laboratory:
     ------------------------------
     Sally McCraven
     781-861-4577
     smccraven@ilww.com




    




For further information:

For further information: For media, Jared Tipton, +1-408-400-8377,
jared.tipton@cepheid.com, for investors, Jacquie Ross, +1-408-400-8329,
investor.relations@cepheid.com, both of Cepheid Corporate Communications; or
Sally McCraven of Instrumentation Laboratory, +1-781-861-4577,
smccraven@ilww.com Web Site: http://www.cepheid.com                
http://www.ilus.com

Organization Profile

CEPHEID

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890